|
|
|
WELCOME TO SOMATICS, THE WORLD LEADER IN ECT INNOVATION AND SALES
|
|
In 1938 the first patient ever to receive ECT made a full recovery. Now, over 90 years later, ECT remains an established treatment for severe depression. The Thymatron device is an FDA-cleared medical device intended to treat catatonia or a severe major depressive episode associated with major depressive or bipolar disorder in patients age 13 years and older who are treatment-resistant or who require a rapid treatment response (Device class II).
|
|
The Thymatron® instrument’s positive safety profile derives from its multiple redundant levels of error protection and operating efficiency.
Several proprietary computer methods in the Thymatron® instrument automatically provide optimal stimulus delivery, seizure quality analysis, and seizure endpoint determination. This information is printed in a concise end-of-treatment report.
|
Please review indications, warnings, cautions, and adverse effects described fully in Thymatron® System IV - Instruction Manual on the DOWNLOADS page of this website. This manual download supersedes and replaces all previous versions, which should be discarded.
This website provides full security by taking no information about visitors.
Phone: 847-234-6761, 800-642-6761 (USA).
Fax: 847-234-6763, E-mail: sales@thymatron.com
|
|
|
|
|
|
©1983-2021 Somatics, LLC. All rights reserved. The Somatics logo and the Thymatron®
name are registered trademarks of Somatics, LLC.
|
|
|
